Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro

Experimental Cell Research

Volumn 315, Issue 14, 2009, Pages 2333-2342

  Krawetz, Roman ^a   Wu, Yiru Elizabeth ^a   Rancourt, Derrick E ^a   Matyas, John ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Bone organ culture; Bone turnover; Osteoblasts; Osteotropic breast cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DATA ANALYSIS; EXPLANT; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; ORGAN CULTURE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL;

BOVINAE; MURINAE;

EID: 67649170400     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.04.026     Document Type: Article

References (26)

1. Galasko C.S. Mechanisms of lytic and blastic metastatic disease of bone. Clin. Orthop. 169 (1982) 20-27
2. Nielsen O.S., Munro A.J., and Tannock I.F. Bone metastases: pathophysiology and management policy. J. Clin. Oncol. 9 (1991) 509-524
3. Thomas G.P., Baker S.U., Eisman J.A., and Gardiner E.M. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J. Endocrinol. 170 (2001) 451-460
4. Gori F., Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Khosla S., and Riggs B.L. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141 (2000) 4768-4776
5. Body J.J., Borkowski A., Cleeren A., and Bijvoet O.L. Treatment of malignancy associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J. Clin. Oncol. 4 (1986) 1177-1183
6. Boyce B.F., Yoneda T., and Guise T.A. Factors regulating the growth of metastatic cancer in bone. Endocr. Relat. Cancer 6 (1999) 3333-3347
7. Neudert M., Fischer C., Krempien B., Bauss F., and Seibel M.J. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int. J. Cancer 107 (2003) 468-477
8. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., Keast P.K., Brassard J.A., O'Farrell A.M., Cherrington J.M., and Pryer N.K. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 20 (2003) 757-766
9. Hiscox S., Morgan L., Barrow D., Dutkowskil C., Wakeling A., and Nicholson R.I. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin. Exp. Metastasis 21 (2004) 201-212
10. Manni A., Washington S., Mauger D., Hackett D.A., and Verderame M.F. Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells. Clin. Exp. Metastasis 21 (2004) 461-467
11. Miller M.E., Holloway A.C., and Foster W.G. Benzo-[a]-pyrene increases invasion in MDA-MB-231 breast cancer cells via increased COX-II expression and prostaglandin E2 (PGE2) output. Clin. Exp. Metastasis 22 (2005) 149-156
12. Shannon K.E., Keene J.L., Settle S.L., Duffin T.D., Nickols M.A., Westlin M., Schroeter S., Ruminski P.G., and Griggs D.W. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin. Exp. Metastasis 21 (2004) 129-138
13. Bäuerle T., Adwan H., Kiessling F., Hilbig H., Armbruster F.P., and Berger M.R. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int. J. Cancer 115 (2005) 177-186
14. Withold W., Schulte U., and Reinauer H. Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Clin. Chem. 42 (1996) 210-217
15. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., and Väänänen H.K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J. Bone Miner. Res. 15 (2000) 1337-1345
16. Janckila A.J., Takahashi K., Sun S.Z., and Yam L.T. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin. Chem. 47 (2001) 74-80
17. Chao T.Y., Ho C.L., Lee S.H., Chen M.M., Janckila A., and Yam L.T. Tartrate-resistant Acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. J. Biomed. Sci. 11 (2004) 511-516
18. Halleen J.M., Alatalo S.L., Janckila A.J., Henning W.W., Markus J.S., and Väänänen H.K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin. Chem. 47 (2001) 597-600
19. Chung Y.C., Ku C.H., Chao T.Y., Yu J.C., Chen M.M., and Lee S.H. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 424-428
20. Demers L.M., Costa L., and Lipton A. Biochemical markers and skeletal metastases. Clin. Orthop. Relat. Res. 415 Suppl (2003) S138-S147
21. Fontana A., Pierre D., and Delmas T.I. Markers of bone turnover in bone metastases. Cancer 88 (2000) 2952-2960
22. Bellahcene A., and Castronovo V. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bull. Cancer 84 (1997) 17-24
23. Mercer R., Miyasaka C., and Mastro A. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin. Exp. Metastasis 5 (2004) 427-435
24. Shaw K.R., Wrobel C.N., and Brugge J.S. Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J. Mammary Gland Biol. Neoplasia 4 (2004) 297-310
25. Pickl M., and Ries C.H. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 3 (2009) 461-468
26. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75-85